Investors in gene-editing and genetic-medicine companies are positioning ahead of third-quarter earnings and upcoming clinical readouts, with Intellia Therapeutics taking center stage after positive data in hereditary angioedema (HAE) and transthyretin amyloidosis (ATTR) lifted sector sentiment. Analysts at Leerink Partners and others have highlighted Intellia’s recent share gains and the company’s forecast of a major commercial opportunity in HAE. The market has bid up several genetic-medicine names on hopes that pivotal data will validate gene-editing as a durable, commercial modality alongside oligonucleotide and antibody therapies. Firms and investors will watch enrollment, regulatory timelines and management commentary closely in Q3 to see whether the rally is supported by sustained clinical and commercial progress.